Methods of using gas-filled microvesicles covalently bound to an antigen

Patent metadata

Field	Value
Publication number	US-9770411-B2
Application number	US-201113996034-A
Country	US
Kind code	B2
Filing date	Dec 21, 2011
Priority date	Dec 24, 2010
Publication date	Sep 26, 2017
Grant date	Sep 26, 2017

Abstract

Gas-filled microvesicles comprising an antigen bound thereto and to aqueous suspensions containing said microvesicles, for use in immunomodulating formulations, in particular as a vaccine. The antigen is covalently bound to a component of the microvesicles envelope. The microvesicles of the invention are particularly effective in the uptake by antigen-presenting cells, in particular dendritic cells.

First claim

The invention claimed is:

1. An immunomodulating treatment method comprising administering to a patient in need thereof a pharmaceutical formulation comprising gas-filled microvesicles with a stabilizing envelope, said microvesicles comprising an antigen covalently bound to a component of said envelope,
wherein the method is performed with no ultrasound irradiation.

2. The method according to claim I wherein said treatment comprises vaccination.

3. The method according to claim 2 wherein said antigen is a vaccine antigen.

4. The method according to claim 1 wherein said treatment comprises a tolerance-inducing treatment.

5. The method according to claim 1 wherein said treatment comprises an immunostimulating treatment.

6. The method according to claim 1 wherein said component is a phospholipid.

7. The method according to claim 6 wherein said phospholipid is a pegylated phospholipid.

8. The method according to claim 1 wherein said antigen is present in a molar amount of from 0.1% to 20% in said envelope.

9. The method according to claim 1 wherein the gas contained in the microvesicles comprises a fluorinated gas.

10. The method according to claim 9 wherein said gas is in admixture with air or nitrogen.

11. The method according to claim 1 wherein said stabilizing envelope comprises at least 50% by weight of a phospholipid.

12. The method according to claim 1 wherein said envelope further comprises an immunomodulating adjuvant.

13. The method according to claim 12 wherein said adjuvant represents from 0.1% to about 50% by mole of the envelope.

14. The method according to claim 1 wherein said antigen is selected from the group consisting of an allergenic antigen, a viral antigen, a bacterial antigen, a fungal antigen, a toxin-derived antigen, a parasitic antigen, a self antigen, a tumor antigen and a mixture thereof.

15. The method according to claim 1 wherein the pharmaceutical formulation comprises an aqueous suspension comprising said gas-filled microvesicles.

16. The method according to claim 15 wherein said aqueous suspension comprising said gas-filled microvesicles is prepared by reconstituting a precursor of said suspension in the form of a dry powdered material with a physiologically acceptable aqueous carrier.

17. A method of vaccinating comprising
administering to a patient in need thereof a suspension of gas-filled microvesicles, with a stabilizing envelope, said microvesicles comprising an antigen covalently bound to a component of said envelope,
wherein the method is performed with no ultrasound irradiation.

18. The method according to claim 17 wherein said microvesicles provide an effective uptake by antigen-presenting cells.

19. A method for increasing the uptake of an antigen by a respective antigen-presenting cell, which comprises contacting said antigen with said cell wherein said antigen is covalently bound to a gas-filled microvesicle,
wherein the method is performed with no ultrasound irradiation.

20. A method according to claim 19 , wherein said antigen-presenting cell is a dendritic cell.

Assignees

• Bioley Gilles
• Corthesy Blaise
• Bussat Philippe
• Lassus Anne
• Schneider Michel
• Bracco Suisse Sa

Inventors

• Bioley Gilles
• Corthesy Blaise
• Bussat Philippe
• Lassus Anne
• Schneider Michel

Classifications

• A61K2039/60

  characteristics by the carrier linked to the antigen · CPC title

• A61K47/6925

  the form being a microcapsule, nanocapsule, microbubble or nanobubble · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61K9/0087 Primary

  Galenical forms not covered by A61K9/02 - A61K9/7023 · CPC title

• A61P37/02

  Immunomodulators · CPC title